Momentum Biotechnologies Acquires OmicScouts GmbH

March 5, 2025

Momentum Biotechnologies, a mass spectrometry–focused contract research organization (CRO) based in Billerica, Massachusetts, has acquired Munich-based OmicScouts GmbH to integrate proteomics capabilities into its drug-discovery service offering. The deal expands Momentum's technical services (chemoproteomics and validated proteomic assays) and provides immediate geographic presence in Europe.

Buyers
Momentum Biotechnologies
Targets
OmicScouts GmbH
Industry
Biotechnology
Location
Bavaria, Germany
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.